Growth trajectory, margins anc client additions to sustain for Laurus Labs

Some of the growth is captured in the price rally, higher valuations

With returns of over 20 per cent, Laurus Labs is by far the best performing pharmaceutical stock over the past three months. In comparison, its peer index, the Nifty Pharma, is struggling to make money for investors shedding a per cent. In fact, barring Sun Pharma and Cipla (10-12 per cent returns), all the pharma companies were in the red in this period. Ongoing price erosion and limited number of launches in the US market, inventory destocking and higher raw material/logistic costs have led to the muted performance of the pharma space.

Amid this, Laurus continues to outperform. Recently, Sharekhan